DelveInsight’s, “Autosomal Dominant Polycystic Kidney Disease Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Autosomal Dominant Polycystic Kidney Disease pipeline landscape.

 

The Autosomal Dominant Polycystic Kidney Disease Pipeline landscape is provided which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease treatment guidelines. The assessment part of the Autosomal Dominant Polycystic Kidney Disease pipeline report embraces, in depth Autosomal Dominant Polycystic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the Autosomal Dominant Polycystic Kidney Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal Dominant Polycystic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Autosomal Dominant Polycystic Kidney Disease Pipeline Report

• DelveInsight’s Autosomal Dominant Polycystic Kidney Disease Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for various indications.
• Leading Autosomal Dominant Polycystic Kidney Disease Companies such as Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and are evaluating Autosomal Dominant Polycystic Kidney Disease drugs candidate to improve the treatment landscape.
• The promising Autosomal Dominant Polycystic Kidney Disease therapies in the pipeline includes GLPG2737, Bardoxolone methyl, Tesevatinib, Venglustat, AT 20494, RGLS 8429, AL 01211, XRx-008, PXL770, and others
• GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with autosomal dominant polycystic kidney disease (ADPKD).
• Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA and European Commission have granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”).

 

Latest News and Developments in the Autosomal Dominant Polycystic Kidney Disease Treatment Landscape

i) In December 2020, we announced the first dosing with GLPG2737 in the Phase 2 MANGROVE trial in patients with ADPKD and in November 2021 full patient recruitment with topline results anticipated in the first half of 2023.

ii) Bardoxolone is currently being studied in FALCON, a Phase 3 study for the treatment of CKD caused by ADPKD, EAGLE, an open-label, extended access trial in patients with CKD caused by Alport syndrome who participated in the CARDINAL trial and patients with ADPKD who participated in the FALCON trial, and AYAME, a Phase 3 study for the treatment of diabetic kidney disease that is being conducted by Kyowa Kirin in Japan.

 

Request a Sample Copy and discover the recent advances in Autosomal Dominant Polycystic Kidney Disease pipeline report @ Autosomal Dominant Polycystic Kidney Disease Pipeline Outlook

 

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal dominant polycystic kidney disease is a genetic disorder characterized by the formation of cysts within the kidneys. Symptoms caused by cyst formation in the kidneys include high blood pressure (hypertension), pain on the sides of the body between the last rib and the hip (flank pain), blood in the urine (hematuria) and progressively poor function of the kidneys (kidney insufficiency).   In most patients, ADPKD eventually progresses to cause end stage renal disease, requiring renal replacement therapy, either dialysis or renal transplantation.

Autosomal dominant polycystic kidney disease is not simply a kidney disorder and other organ systems of the body can potentially be affected (multisystem disorder) by the development of cysts. The specific symptoms present in each person depend upon the specific organ systems involved. The liver, pancreas, a membrane covering the spinal cord and brain (arachnoid membrane), the prostate, and the glands of the male reproductive tract that produce fluid that is part of semen (seminal vesicles) may become involved. Abnormalities affecting the heart and blood vessels (cardiovascular system) may also occur in individuals with ADPKD. ADPKD usually does not become apparent until the fourth or fifth decade and was once known as “adult” polycystic kidney disease. However, it has been reported in children and infants. ADPKD is caused by mutations of one of two genes that create certain proteins essential for the proper health of the kidneys and other parts of the body. Approximately 85 % have ADPKD1, the most aggressive form of the disease; those with ADPKD2 progress to kidney insufficiency about 20 years later.

 

Autosomal Dominant Polycystic Kidney Disease Pipeline Insight

“Autosomal dominant polycystic kidney disease Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autosomal dominant polycystic kidney disease pipeline landscape is provided which includes the disease overview and Autosomal dominant polycystic kidney disease treatment guidelines. The assessment part of the report embraces, in depth Autosomal dominant polycystic kidney disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal dominant polycystic kidney disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Autosomal Dominant Polycystic Kidney Disease Emerging Drugs

• GLPG2737: Galapagos NV
• Bardoxolone methyl: Reata Pharmaceuticals

 

Learn more about the novel and emerging Autosomal Dominant Polycystic Kidney Disease pipeline therapies @ Autosomal Dominant Polycystic Kidney Disease Clinical Trials

 

Autosomal Dominant Polycystic Kidney Disease Pipeline Therapeutics Analysis

There are approx. 12+ key companies which are developing the therapies for Autosomal dominant polycystic kidney disease. The companies which have their Autosomal dominant polycystic kidney disease drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.

 

Vascular Dementia Pipeline Report

• The report provides detailed insights about emerging therapies for Vascular Dementia treatment and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vascular Dementia Treatment.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The Vascular Dementia Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Vascular Dementia market.

The Vascular Dementia Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third party sources etc.

 

Scope of the Vascular Dementia Pipeline Report

• Coverage- Global
• Vascular Dementia Companies- Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others
• Vascular Dementia Therapies- GLPG2737, Bardoxolone methyl, Tesevatinib, Venglustat, AT 20494, RGLS 8429, AL 01211, XRx-008, PXL770, and others
• Autosomal dominant polycystic kidney disease Pipeline Assessment by Product Type
• Autosomal dominant polycystic kidney disease Pipeline Assessment by Stage and Product Type
• Autosomal dominant polycystic kidney disease Pipeline Assessment by Route of Administration
• Autosomal dominant polycystic kidney disease Pipeline Assessment by Stage and Route of Administration
• Autosomal dominant polycystic kidney disease Pipeline Assessment by Molecule Type
• Autosomal dominant polycystic kidney disease Pipeline Assessment by Stage and Molecule Type
• Autosomal dominant polycystic kidney disease- Market Drivers and Barriers
• Autosomal dominant polycystic kidney disease- Future Perspectives and Conclusion
• Autosomal dominant polycystic kidney disease Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Autosomal dominant polycystic kidney disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Autosomal dominant polycystic kidney disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Bardoxolone methyl: Reata Pharmaceuticals
9. Mid Stage Products (Phase II)
10. GLPG2737: Galapagos NV
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. AL 01211: AceLink Therapeutics
14. Preclinical and Discovery Stage Products
15. AT 20494: Anakuria Therapeutics
16. Inactive Products
17. Autosomal dominant polycystic kidney disease Key Companies
18. Autosomal dominant polycystic kidney disease Key Products
19. Autosomal dominant polycystic kidney disease- Unmet Needs
20. Autosomal dominant polycystic kidney disease- Market Drivers and Barriers
21. Autosomal dominant polycystic kidney disease- Future Perspectives and Conclusion
22. Autosomal dominant polycystic kidney disease Analyst Views
23. Autosomal dominant polycystic kidney disease Key Companies
24. Appendix

 

For further information on the Autosomal dominant polycystic kidney disease Pipeline therapeutics, reach out to Autosomal dominant polycystic kidney disease Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/